We serve Chemical Name:3-[3-(3,4-dimethylphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid CAS:649774-33-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-[3-(3,4-dimethylphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid
CAS.NO:649774-33-4
Synonyms:Benzoic acid,3-[3-(3,4-dimethylphenoxy)-2-oxo-1-pyrrolidinyl]
Molecular Formula:C19H19NO4
Molecular Weight:325.35800
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:66.84000
Exact Mass:325.13100
LogP:3.25090
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzoic acid,3-[3-(3,4-dimethylphenoxy)-2-oxo-1-pyrrolidinyl] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid,3-[3-(3,4-dimethylphenoxy)-2-oxo-1-pyrrolidinyl] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid,3-[3-(3,4-dimethylphenoxy)-2-oxo-1-pyrrolidinyl] Use and application,Benzoic acid,3-[3-(3,4-dimethylphenoxy)-2-oxo-1-pyrrolidinyl] technical grade,usp/ep/jp grade.
Related News: This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. 3-[3-(3,4-dimethylphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid manufacturer High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies. 3-[3-(3,4-dimethylphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid supplier What’s the background? 3-[3-(3,4-dimethylphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid vendor This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. 3-[3-(3,4-dimethylphenoxy)-2-oxopyrrolidin-1-yl]benzoic acid factory High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.